Pharmacological WEE1 inhibition as a strategy to overcome cisplatin resistance in non-seminoma testicular cancer: insights from preclinical models

Key Points

• Cisplatin resistance is a major challenge in treating non-seminoma testicular cancer.
• WEE1 inhibition significantly enhances the effectiveness of cisplatin in preclinical models.
• This study utilizes various preclinical models to analyze the effects of WEE1 inhibitors on cancer cells.
• The findings support the potential for new therapeutic strategies to improve treatment outcomes in patients.